Drug-induced fibrotic valvular heart disease (Q33845974)

29 July 2017

1 reference

title

Drug-induced fibrotic valvular heart disease (English)

1 reference

29 July 2017

author

Dimitri P Mikhailidis

object named as

Dimitri P Mikhailidis

1 reference

29 July 2017

author name string

Sanjeev Bhattacharyya

1 reference

29 July 2017

Anthony H Schapira

1 reference

29 July 2017

Joseph Davar

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

29 July 2017

1 reference

29 July 2017

volume

374

1 reference

29 July 2017

issue

9689

1 reference

29 July 2017

page(s)

577-585

1 reference

Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Cardiac and pulmonary fibrosis during methysergide therapy for headache

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Development of heart valve lesions during methysergide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Cardiac murmurs and endocardial fibrosis associated with methysergide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Valvular heart disease associated with ergotamine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

1 reference

7 January 2021

Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

1 reference

7 January 2021

Aminorex to fen/phen: an epidemic foretold

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Drugs and valvular heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Valvular heart disease associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Appetite suppressants and valvular heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

The progression of fenfluramine-associated valvular heart disease assessed by echocardiography

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Treatment options in the modern management of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Valvular heart disease in patients taking pergolide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Pergolide use in Parkinson disease is associated with cardiac valve regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Fibrotic valvular heart disease subsequent to bromocriptine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Dopamine agonists and the risk of cardiac-valve regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Diagnostic and prognostic value of N-terminal pro B-type natriuretic peptide (NT-proBNP) in patients with chronic aortic regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Pergolide in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Advances in the treatment of prolactinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Cabergoline and the risk of valvular lesions in endocrine disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Trends in ecstasy use in the United States from 1995 to 2001: comparison with marijuana users and association with other drug use.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

A Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Mitogenic effect of serotonin on vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Stimulation of aortic smooth muscle cell mitogenesis by serotonin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Long-term serotonin administration induces heart valve disease in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Chronic fenfluramine administration increases plasma serotonin (5-hydroxytryptamine) to nontoxic levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

Serotonin transporter mechanisms and cardiac disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960252-X

7 January 2021

10.1016/S0140-6736(09)60252-X

Identifiers

DOI

1 reference

29 July 2017

1 reference